| Home-based zoledronic acid infusion therapy in patients with solid tumours: compliance and patient-nurse satisfaction. | |
| | |
MedLine Citation:
|
PMID: 23299561 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
PURPOSE: This study aimed to explore patient and nurse satisfaction, compliance with best practice, technical feasibility and safety of home infusion of the bisphosphonate zoledronic acid (ZOL). METHODS: This was a prospective 1-year survey of home ZOL therapy (4 mg Zometa®, 15-min i.v., every 3-4 weeks) in patients with bone metastases secondary to a solid malignancy. A physician questionnaire, nurse satisfaction/feasibility questionnaire and patient satisfaction questionnaire were administered at several time-points. RESULTS: Physician participation rate was 56.5 % (87/154). Physicians enrolled 818 patients visited by 381 predominantly community nurses. Of the 788 case report forms received, 763 met inclusion criteria. Patient characteristics were as follows: median age, 68 years (30-95); M/F, 40/60; ECOG-PS 0 or 1, 78.6 %;and primary tumour site, breast (55.2 %), prostate (28.4 %), lung (7.2 %) or other (9.4 %). Nurse satisfaction rates were high: organisation of home ZOL therapy, 90.9 %; ease of infusion, 96.7 %; patient-nurse relationship, 97.5 %; and relationship with hospital staff, 73 %. Patient satisfaction was also very high (95.3 %). The main reasons were quality of the nurse-patient relationship (57.6 %), less travel/waiting (68.8 %), home environment (52.9 %) and less disruption to daily routine (36.6 %). ZOL therapy was well tolerated, the discontinuation rate due to adverse events (including deaths whether related to diseases progression or not) was 33.6 %. The incidence of osteonecrosis of the jaw was 0.6 % and of fractures, 0.2 %. Practitioner compliance with best practice was 76.7-83.7 % for recommended and/or tolerated dosage, 73 % for dental hygiene checks at inclusion and 48-56 % thereafter, 66 % for pre-infusion hydration, and often undocumented for calcium/vitamin D supplementation. CONCLUSIONS: Home ZOL therapy was well tolerated. Both patient and nurse satisfaction were very high. However, better compliance with best practice should be encouraged. |
| | |
Authors:
|
Thierry Lebret; Jean-Loup Mouysset; Alain Lortholary; Claude El Kouri; Laurent Bastit; Meryem Ktiouet; Khemaies Slimane; Xavier Murraciole; Stéphane Guérif |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2013-1-9 |
Journal Detail:
|
Title: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer Volume: - ISSN: 1433-7339 ISO Abbreviation: Support Care Cancer Publication Date: 2013 Jan |
Date Detail:
|
Created Date: 2013-1-9 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9302957 Medline TA: Support Care Cancer Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Hôpital Foch/Urology Department, Université Versailles St Quentin en Yvelines, 40 rue Worth BP 36, 92151, Suresnes Cedex, France, t.lebret@hopital-foch.org. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Naturalistic study on the effectiveness of psycho-oncological interventions in cancer patients and t...
Next Document: Disease-Specific Quality-of-Life Questionnaires in Rhinitis and Rhinosinusitis: Review and Evaluatio...